Navigation Links
Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
Date:11/10/2010

PITTSBURGH, Nov. 10, 2010 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has determined the final conversion rate applicable to its 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") that will be converted into common stock of the company effective as of November 15, 2010.  Mylan has determined that, in accordance with the governing provisions of the company's Amended and Restated Articles of Incorporation, as amended, each share of Preferred Stock will be converted at the close of business on November 15, 2010 into 58.5480 shares of common stock of the company, the minimum conversion ratio permitted by the Articles.  This reflects the strong stock performance of the company since the preferred stock was issued.  Accordingly, an aggregate of 125,234,172 shares of common stock will be issued to record holders of Preferred Stock on November 15, 2010.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
(Date:9/4/2015)... 2015  Pharmaceutical companies today rely heavily on ... Specialists (FBMS) to build and strengthen vital relationships ... in critical therapeutic areas. To ... are expanding the critical MSL function into global ... objectives and to achieve regional consistency, compliance, and ...
(Date:9/4/2015)... , Sept. 4, 2015  Dohmen Company CEO ... the Metropolitan Milwaukee Association of Commerce,s annual ,Future 50, ... the Pfister Hotel. The ,Future 50, Awards highlights the ... and young firms headquartered in the seven-county ... called Milwaukee home for more ...
Breaking Medicine Technology:Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2
... ... 7 , Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) and ... of positive data from a phase 1 study of TRU-016 in ... 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a ...
... , HOBOKEN, N.J., Dec. 7 ... the U.S. Food and Drug Administration has approved ... in patients with all types of von Willebrand disease (VWD). Wilate® ... Factor VIII Concentrate (Human) that demonstrated efficacy for all types of ...
Cached Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5
(Date:9/4/2015)... ... September 04, 2015 , ... ... communities, is launching a charity effort to provide for the family of Grace, ... an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability ...
(Date:9/4/2015)... ... 2015 , ... Inmar announced today that its regulatory experts ... Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With the complex ... industry, it can be difficult for companies to navigate, stay abreast of all ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... ... recipient of three separate “Partner of the Year” awards at this year’s Microsoft ... being named Microsoft’s 2015 “Partner of the Year” Award Winner for Data Platform ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... technology is now available at CitiDent. CEREC is a newer method for creating ... saving time for patients by eliminating the need for multiple appointments, CEREC produces ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL who ... the Ironman World Championships in Kona on October 10th. , Mike is running the ... (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... included nearly 57,000 women who had been followed for ... -- Hormone therapy may lower a woman,s risk of ... the hormones. , This new finding, published in the ... , further complicates an already murky picture of the ...
... SANTA CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... today that the,Company will report fourth quarter and fiscal ... the close of market. Financial results will,be released over ... on the,Investor Relations section of the Company,s website at, ...
... Calif., Jan. 8 TEAC America, Inc. launches its,next ... dye-sublimation disc printer available, during the CES Show at,the ... The P-55C printer can be integrated ... Discathlon 2. With TEAC,s,AL220S and AL550S, customers can ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... officer. Formerly president and chief operating officer,Popovits is ... In addition, G.,Bradley Cole has been appointed as chief ... chief financial officer, reporting to Popovits. , ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
Cached Medicine News:Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Medicine Products: